BeOne Medicines registers Phase 1 bioavailability study for PRMT5 inhibitor BGB-58067

BeOne Medicines opened one new registry item this week, a Phase 1 pharmacokinetics study, while an earlier BeiGene head and neck cancer trial remains in the record with results posted.

• BGB-58067, a PRMT5 inhibitor designed for cancers missing the MTAP gene, is being tested in "NCT07712640," a Phase 1 crossover study now recruiting in healthy adults. BGB-58067 has been designed to work in cancer cells that are missing a gene called MTAP (about 15% of all cancers).¹ The trial will enroll about 32 participants in Australia¹ to compare a new tablet formulation, F-02, against the existing F-01 formulation and to assess food effects, with actual start listed as 2026-07-21.
• Tislelizumab, alone and combined with surzebiclimab and/or alcestobart, was tested as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma in "NCT05909904," a completed Phase 2 study sponsored by BeiGene, with results first posted 2026-07-14. The study will enroll approximately 160 participants.²